[在耳鼻喉疾病中葡萄糖皮质激素耐药性的进展]
1Department of Otorhinolaryngology，Head and Neck Surgery，Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University，Nanjing，210008，China.
概括
葡萄糖皮质类药物 (GC) 对于治疗内耳和鼻疾病至关重要,但耐药性限制了它们的有效性. 本综述探讨了GC耐药性机制,以寻找更好的治疗方法用于耳鼻喉科患者.
科学领域:
- 耳鼻喉科 耳鼻喉科 耳鼻喉科
- 内分泌学 在内分泌学.
- 免疫学 免疫学 免疫学
背景情况:
- 葡萄糖皮质类药物 (GC) 是各种耳鼻喉疾病的标准治疗方法,包括自身免疫性内耳疾病,突然的神经神经听力损失,梅尼尔氏病和鼻炎.
- 临床实践中的一个重大挑战是葡萄糖皮质醇耐药性,这会影响这些疾病的治疗疗效.
- 在耳鼻喉科中驱动葡萄糖皮质激素耐药性的潜在机制尚未完全理解.
研究的目的:
- 综合审查葡萄糖皮质激素耐药性的已知机制.
- 检查来自葡萄糖皮质醇受体依赖和独立路径的葡萄糖皮质醇耐药性.
- 总结了解葡萄糖皮质醇耐药性的最新进展,特别是在耳鼻喉疾病中.
主要方法:
- 关于葡萄糖皮质醇耐药性的现有研究的文献综述.
- 对聚焦于葡萄糖皮质体受体因子的研究进行分析.
- 对对抗性有助于产生非葡萄糖皮质体受体因子的研究进行审查.
主要成果:
- 葡萄糖皮质类药物耐药性涉及受体和非受体水平的复杂相互作用.
- 正在阐明有助于耳鼻喉疾病耐药性的特定分子机制.
- 目前的研究强调了葡萄糖皮质醇耐药性途径的异质性.
结论:
- 了解葡萄糖皮质醇耐药性的多方面的机制对于改善治疗结果至关重要.
- 对葡萄糖皮质激素耐药性的进一步研究是必要的,以制定克服它的策略.
- 对于患有抗葡萄糖皮质醇的耳鼻喉疾病的患者来说,确定替代治疗选择是必不可少的.
相关概念视频
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
114
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
114
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
234
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
234
01:26COPD: Management Using Bronchodilators and Corticosteroids
194
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
194
01:27Open Angle Glaucoma: Treatment
427
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
427
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
267
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
267
01:17Drugs Used in Lower Respiratory Disorders: Overview
397
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
397